Unregulated Peptides The Grey Market Boom Turning Consumers Into Test Subjects

A subculture once confined to the margins of competitive bodybuilding has migrated into the mainstream wellness economy at remarkable speed. The proliferation of unregulated peptide compounds, sold openly online and promoted by a growing cohort of social media influencers, represents one of the more striking intersections of consumer demand, regulatory failure, and commercial opportunism to emerge in recent years. What began as niche self-experimentation has evolved into a multi-layered grey market, drawing in not only fitness enthusiasts but also middle-aged women, biohackers, and longevity seekers, all in pursuit of compounds that remain, in most cases, entirely unapproved for human use.

In biochemical terms, peptides are short chains of amino acids that function as cellular signalling agents. Naturally occurring peptides govern processes including hormone regulation and tissue repair. Laboratory-synthesised equivalents are designed to mimic or amplify those biological functions. The online market has positioned this science, selectively and often misleadingly, as a chemical shortcut to outcomes ranging from enhanced skin quality and accelerated recovery to cognitive improvement and dramatic weight loss. The commercial infrastructure supporting this narrative is sophisticated, and the risks it generates are substantial.

The trajectory of Joe Smith, a Sheffield-based online trainer who built a following of 56,000 on TikTok under the handle @joelikesgym, accumulating 4.5 million likes before his account was banned in March 2026, illustrates the model clearly. Smith’s entry point was Melanotan II, widely referred to as the “Barbie drug” or the “tan jab”, a compound that stimulates melanin production to accelerate tanning. He sourced it from an online dealer in late 2024 and progressed to a range of additional compounds, including retatrutide, BPC-157, TB-500, and GHK-Cu, the latter marketed under the colloquial name “Smurf Juice”. His remaining Instagram and YouTube accounts carry affiliate links to a supplier called Clova Health Ltd, a company registered at a residential address in Luton, Bedfordshire, from which Smith earns commission on sales.

Melanotan II is unregulated and its use has attracted formal warnings from regulatory authorities in the United Kingdom, the United States, Denmark, and Ireland. Cancer Research UK has stated that it does not protect against skin damage from ultraviolet exposure, and a 2021 study found that users exhibited elevated rates of sun-seeking behaviour associated with increased skin cancer risk. Dr Rachael Dickman, a lecturer at University College London who researches peptide therapeutics, is unequivocal on its legal status. “Melanotan is illegal in the UK,” she states. “The health risks are evident.”

The commercial ecosystem in which these compounds circulate relies on a well-worn regulatory loophole. Products are labelled “for research purposes only”, a designation that suppliers and influencers repeat as a form of legal insulation. The Medicines and Healthcare products Regulatory Agency (MHRA) has made clear that where products are promoted or used as medicines, they fall within the scope of existing legislation regardless of how they are labelled. Dr Dickman draws attention to the quality control problem that underlies the safety concern. “We buy those sorts of things to do our research,” she explains. “We test them when they arrive. Often they’re not clean. The process to make something suitable to inject into a person is very different to the process to make something suitable for use in the lab.”

The compounds most frequently encountered in the grey market carry varying degrees of scientific legitimacy, which is precisely what makes the landscape so difficult to navigate. Retatrutide, a GLP-1 receptor agonist that is currently in phase-three clinical trials conducted by Eli Lilly under the colloquial names “Red Tide” and “Triple G”, has no approved pathway for patient use outside of those trials. BPC-157, a synthetic peptide with a growing body of preclinical research associated primarily with the University of Zagreb and Professor Predrag Sikiric, has demonstrated potential in studies relating to gastrointestinal healing, tendon repair, and circulatory restoration; however, the human data remains limited, and long-term safety profiles are unknown. TB-500, frequently combined with BPC-157 in a protocol known as the “Wolverine stack”, is promoted for its capacity to stimulate new blood vessel formation and reduce inflammation, though it similarly lacks regulatory approval for general use in humans.

Professor Sikiric, who first isolated BPC-157 in the 1990s, is careful to distinguish between the scientific record and the grey market through which the compound now circulates. He maintains that BPC-157’s toxicology record is unusually reassuring, noting that a lethal dose could not be identified in laboratory conditions, and that in a European phase-two study, adverse effects were more prevalent in the placebo group than among treated participants. He also rejects the concern, raised by some critics, that the compound’s pro-vascular properties might stimulate tumour growth, arguing that BPC-157 restores order to damaged blood vessels through selective regulation rather than promoting indiscriminate vascular expansion. Nonetheless, he acknowledges that no medicine should be used outside an approved framework, and declines to endorse the purchase of unapproved substances through online channels.

The demand side of this market is not limited to fitness circles. Kim Constable, a 46-year-old entrepreneur and former professional bodybuilder based in Belfast, began using peptides approximately one year ago while managing the symptoms of perimenopause. She was introduced to micro-dosing semaglutide via a podcast and subsequently obtained a private prescription from a GP. Her self-reported outcomes, which include resolution of gluteal tendinopathy, relief from brain fog, and improved sleep quality within days of commencing treatment, have been widely disseminated through her online platforms. She now self-administers approximately 12 different peptides in rotating cycles, sources compounds directly from China, and has them tested for purity in a United Kingdom laboratory. She participates in a Telegram group of 4,600 members, growing at roughly 100 members per day, with a demographic that is predominantly women aged between 55 and 70.

The clinical community remains largely opposed to the unregulated use of these compounds. Dr Rupert Critchley, a general practitioner and founder of Viva Skin Clinics in London, which does not administer injectable peptides, summarises the medical position plainly. “As doctors, we rely on medicines that have gone through proper clinical testing. That process hasn’t happened with a lot of these compounds, which makes their safety and efficacy uncertain.” His view is that social media has materially accelerated demand, particularly within fitness and aesthetics communities where peptides are increasingly framed as a less aggressive alternative to anabolic steroids. “From a medical perspective, I wouldn’t recommend using unregulated peptides,” he states.

Eli Lilly’s posture on the grey market surrounding retatrutide is notably proactive. The company is engaged with governments, regulators, and organisations including the World Health Organization to publicise the risks of unregulated sourcing, is running a public awareness campaign across the London Underground, and assisted in the removal of thousands of social media accounts and websites involved in the illegal sale of its medicines and counterfeit variants in the preceding year. Dr Emily Pegg, Eli Lilly’s associate vice-president, has disclosed that internal testing of counterfeit products identified “critical issues” capable of causing “significant harm”. Her caution to consumers is direct. “By buying medicine from social media, you are rolling the dice with your health.”

The scale of the counterfeit medicines trade that underpins this market places the peptide boom in a sobering macroeconomic context. The global trade in counterfeit pharmaceuticals is now estimated at up to USD 432 billion annually, with some analysts suggesting it has surpassed human trafficking, arms dealing, and narcotics as the most lucrative illicit market in the world. Europol’s Operation Shield identified networks manufacturing counterfeit peptide and weight-loss drugs alongside anabolic steroids in clandestine laboratories. In October 2025, MHRA officers conducted what was described as the largest single seizure of trafficked weight-loss medicines on record, from a warehouse in Northampton, with much of the consignment labelled as retatrutide. A subsequent operation in Lincolnshire yielded nearly 2,000 doses produced in facilities operating without sterile controls or quality assurance protocols.

The political dimension has also shifted. Robert F. Kennedy Jr., the United States Secretary of Health, announced in March 2026 a rollback of restrictions on several peptides including BPC-157 and GHK-Cu as part of his “Make America Healthy Again” platform. The intervention signals a regulatory philosophy that views peptides as occupying the frontier of personalised, preventative medicine rather than as a category of unproven risk. The divergence between this position and the approach taken by the MHRA and European regulators is likely to have commercial and compliance implications for operators on both sides of the Atlantic.

What the peptide market ultimately presents is a structural tension familiar to any analyst of emerging health sectors: genuine scientific promise, insufficient human data, a significant and growing consumer base prepared to accept personal risk, sophisticated commercial supply chains operating in regulatory grey zones, and institutional frameworks that are reactive rather than anticipatory. Some compounds in this space will, over time, progress through clinical trials and achieve approved status. Others will not. In the interim, a substantial number of individuals are administering substances of uncertain provenance and unverified purity into their own bodies, guided principally by online influencers operating on commission. The asymmetry between the enthusiasm driving demand and the evidence base supporting it remains, for now, the defining characteristic of this market.